Project Grant R35CA294015
Award Date 8/1/25
Completion Date 7/31/32
Dollars Obligated $847K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This Project Grant award from the National Institutes of Health's (NIH) National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $901,205 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct genome-wide studies examining how tumor immune editing in early-stage cancers leads to immune evasion and suppression. The research aims to identify key genes, pathways, and processes that are epigenetically repressed during early tumor...
- This $858,186 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports a research project titled "Decoding T Cell Clonotypes, Biology and Predictive Biomarkers Associated with Immune Checkpoint Myocarditis." The project aims to investigate the mechanisms underlying immune-related myocarditis, a potentially fatal adverse event associated with immune checkpoint inhibitor cancer therapies. Using...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...
- This federal Project Grant award of $135,513, provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program, supports research to elucidate the transcriptional mechanisms underlying cognitive impairment induced by cancer therapies, a critical issue affecting cancer survivors. The research, conducted by Beth Israel Deaconess Medical Center, Inc., a prominent academic medical center in Boston, Massachusetts, aims to identify candidate transcription factor...
- This federal Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) provides $153,348 to The Trustees of Columbia University in the City of New York to conduct in-depth mechanistic and in vivo functional studies of single-nucleotide variants (SNVs) that modulate T cell activity for cancer immunotherapies. The research aims to define the mechanisms by which certain PIK3CD SNVs enhance T cell activity and evaluate their impact in murine...
- This federal Project Grant award of $443,564 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research to develop a novel cancer vaccination platform using engineered skin commensal bacteria. The primary objective is to leverage a prevalent skin bacterium, Staphylococcus epidermidis, to stimulate tumor-specific T cell immunity and enhance cancer immunotherapy. The research aims to overcome barriers in genetic engineering of clinically relevant skin...
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- The National Cancer Institute (NCI) awarded a $547,945 Project Grant under CFDA 93.396 (Cancer Biology Research) to The Johns Hopkins University to conduct research on the pathogenesis of immune checkpoint inhibitor-induced myocarditis. The project aims to investigate how biological factors such as prior cardiac injury, age, and sex modulate the risk of this adverse event, which occurs in 1-2% of cancer patients receiving immune checkpoint inhibitor therapy but can be fatal in up to 50% of...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $620,820.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the role of the transcription factor CREB5 in driving immune therapy resistance in cancer. The research aims to: 1) understand the molecular mechanisms governing CREB5 regulation and transcription, 2) identify CREB5-interacting proteins that drive collagen matrix...
- This Project Grant award, titled "Immune Evasion through HLA-E in Diffuse Large B-Cell Lymphoma: Defining its Regulation and Cellular Interactions", is funded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) for $241,884.00. The award will be carried out by the Dana-Farber Cancer Institute, Inc. (DFCI) from September 3, 2025 through August 31, 2030. The project aims to characterize the role of the non-classical HLA-E molecule in immune evasion by diffuse large...